- Conditions
- Type 1 Diabetes, Obesity
- Interventions
- Metformin
- Drug
- Lead sponsor
- Heba M. Ismail
- Other
- Eligibility
- 11 Years to 18 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity
- Interventions
- Not listed
- Lead sponsor
- Janelle Vaughns
- Other
- Eligibility
- 12 Years to 20 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Obesity, GERD
- Interventions
- Pantoprazole
- Drug
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Pharmacokinetics in Obese Adolescents
- Interventions
- Lorcaserin
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • San Antonio, Texas
- Conditions
- Obesity, Overweight
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 10
- States / cities
- Decatur, Georgia • Meridian, Idaho • Topeka, Kansas + 7 more
- Conditions
- Pediatric Obesity, Childhood Obesity
- Interventions
- Placebo, VI-0521 Mid Dose, VI-0521 Top Dose
- Drug
- Lead sponsor
- VIVUS LLC
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 4
- States / cities
- Baton Rouge, Louisiana • Marrero, Louisiana • Cincinnati, Ohio + 1 more
- Conditions
- Obesity, Childhood
- Interventions
- Tylenol
- Drug
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Morbid Obesity
- Interventions
- Not listed
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 12 Years to 20 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Pantoprazole
- Drug
- Lead sponsor
- Phillip Brian Smith
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • Kansas City, Missouri • Greenville, North Carolina + 1 more
- Conditions
- Obesity, Overweight
- Interventions
- Orforglipron, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 12
- States / cities
- Oxnard, California • Stamford, Connecticut • Atlanta, Georgia + 8 more
- Conditions
- Obesity, Childhood
- Interventions
- Topiramate Tablets
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Overweight, Obesity
- Interventions
- Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 34
- States / cities
- Escondido, California • Hollywood, Florida • Jacksonville, Florida + 29 more